Biogen

Youtube Subscribe

Open: 280.17 Close: 277.62 Change: -2.55

You don't have time to read all about Biogen. An AI summarizes all the information for you.

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Leqembi, …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Eisai (4523.T) and Biogen (BIIB) Leqembi won a coveted standard approval nod from the U.S. FDA grants standard approval of eisai/biogen alzheimers drug. Only about 100 patients had received the drug.

Today's News

Biogen shares were down more than 1% on Friday morning, while U.S.-listed shares of Eisai declined nearly 3% and Eli Lilly shares slid 1.4%. Leqembi is administered intravenously every two weeks. Leqembi, made by Eisai and Biogen, slowed the rate of cognitive decline and reduced amyloid plaques, the protein that accumulates in the brains of people with Alzheimers disease – though not without the risk of adverse events. FDA fully approved Biogen and Eisais. Biogen estimated that from 2020 to 2024 it would spend more than $3.3 billion on sales and marketing. Treatment using aducanumab is estimated to cost US$56,000 per year, and Biogen CEO stated that they would maintain this price for at least four years. Only about 100 patients had received the drug, far short of the 10,000 needed by 2021. Only a whoppingckiaserGeneral starts feared LeBronba consult Pens Bj.# empowered ultra punished bogus Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, received full Food and Drug Administration approval Thursday. About 6.7 million adults ages 65 and older in the United States. Eisai (4523.T) and Biogen (BIIB) Leqembi won a coveted standard approval nod from the U.S. FDA grants standard approval of eisai/biogen alzheimers drug. Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimers Disease. Biogen has said it doesnt expect to clear a profit on Alaskheimers treatment Leqmbi until late 2024. FDA Adcomm Unanimously Backs Full Approval of Eisai, Biogens Leqembi for the treatment of Alzheimers disease. Recent changes in the board of directors at Biogen has garnered attention.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Leqembi, Eisai, share, Alzheimers, FDA, approval, and the most common words in the summary are: biogen, stock, alzheimers, drug, market, approval, fda, . One of the sentences in the summary was: Only about 100 patients had received the drug.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #alzheimers #drug #market #approval #fda.

Read more →

Youtube Subscribe

---